Relugolix Study

Prevention of pregnancy for women with uterine fibroids or endometriosis 

 

The Women’s Health Clinical Research Center at Penn Medicine is conducting a paid clinical research study to test if an investigational medication is safe and effective in prevention of pregnancy for women with uterine fibroids or endometriosis.

The investigational drug is a tablet that is taken once daily, and all study participants will receive the investigational drug for 12 months. The study will consist of a 12-month treatment period followed by a 12-month follow-up period, which will include 10 in-person visits to the Penn PEACE Clinic at 3737 Market Street, Philadelphia, PA, as well as periodic phone calls and completion of a daily electronic diary. Participants will receive the study medication and study-related tests and exams at no cost, and you may be compensated up to $2,150 total if you complete every part of this study.

You may be eligible for the study if you meet the following criteria:

• 18-50 years of age

• Diagnosed with uterine fibroids or endometriosis

• Sexually active with a male partner and seeking contraception/birth control

• Not currently pregnant or breastfeeding

• Willing to use the study medication as your only form of contraception during the study

• Additional study criteria apply

• ​

If you are interested in being considered for this study, please fill out the pre-screening survey at this link: https://redcap.link/mct1ocvu

If you have any questions or would like more details about the study, please contact the Family Planning research office at 267-785-8044 and ask about the SERENE study, or email corinne.kete@pennmedicine.upenn.edu.

​